BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that its collaborator, Genentech, Inc., has initiated a phase Ib clinical trial of SGN-40 in combination with Velcade® (bortezomib) for patients with relapsed or refractory multiple myeloma. This is the sixth ongoing clinical trial to evaluate SGN-40 either as a single agent or in combination with standard therapies for non-Hodgkin lymphoma and multiple myeloma.
